Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?

Core Viewpoint - Travere Therapeutics (TVTX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ending December 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.03 per share, reflecting a year-over-year increase of +104.1% [3]. - Expected revenues are projected to be $142.46 million, representing a 90.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.07% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Travere is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +775.01%, suggesting a bullish outlook on the company's earnings [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Travere was expected to post a loss of $0.31 per share but instead reported earnings of $0.28, resulting in a surprise of +190.32% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Travere is positioned as a compelling candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [17].